Huntington National Bank Has $241,000 Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Huntington National Bank trimmed its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 6.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,320 shares of the medical instruments supplier’s stock after selling 90 shares during the period. Huntington National Bank’s holdings in ICU Medical were worth $241,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Silvercrest Asset Management Group LLC grew its position in shares of ICU Medical by 109.4% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after purchasing an additional 145,485 shares during the period. Victory Capital Management Inc. lifted its stake in ICU Medical by 2,966.3% in the second quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock valued at $16,844,000 after buying an additional 137,222 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of ICU Medical by 327.8% in the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock valued at $16,158,000 after buying an additional 104,264 shares during the period. Granite Investment Partners LLC bought a new stake in shares of ICU Medical during the second quarter worth $10,650,000. Finally, F M Investments LLC acquired a new stake in shares of ICU Medical during the second quarter worth $10,175,000. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Stock Down 2.4 %

ICUI stock opened at $167.86 on Monday. The company has a market cap of $4.11 billion, a price-to-earnings ratio of -36.73 and a beta of 0.66. ICU Medical, Inc. has a twelve month low of $82.82 and a twelve month high of $196.26. The business has a 50 day moving average price of $176.43 and a two-hundred day moving average price of $143.31. The company has a quick ratio of 1.08, a current ratio of 2.29 and a debt-to-equity ratio of 0.75.

Wall Street Analyst Weigh In

ICUI has been the subject of a number of research analyst reports. StockNews.com lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, November 12th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp boosted their target price on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Jefferies Financial Group initiated coverage on shares of ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 price target for the company. Finally, Raymond James boosted their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, ICU Medical currently has an average rating of “Moderate Buy” and a consensus price target of $173.00.

Insider Buying and Selling

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This represents a 16.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total value of $2,141,520.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $18,665,666.78. This represents a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,502 shares of company stock worth $6,573,496. Insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.